Evergreen Capital Management LLC Has $2.75 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Evergreen Capital Management LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 362.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,865 shares of the biopharmaceutical company's stock after purchasing an additional 3,030 shares during the quarter. Evergreen Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $2,753,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Geode Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after buying an additional 155,369 shares in the last quarter. Dodge & Cox lifted its holdings in shares of Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock valued at $1,653,543,000 after purchasing an additional 9,381 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Regeneron Pharmaceuticals by 7.9% in the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after purchasing an additional 149,124 shares during the period. Loomis Sayles & Co. L P increased its stake in Regeneron Pharmaceuticals by 33.4% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after purchasing an additional 393,997 shares in the last quarter. Finally, Amundi raised its holdings in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after buying an additional 487,489 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. UBS Group downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday. They issued an "overweight" rating and a $695.00 target price for the company. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Finally, Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $950.76.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded up $18.49 during trading hours on Tuesday, hitting $579.98. The stock had a trading volume of 172,162 shares, compared to its average volume of 711,772. Regeneron Pharmaceuticals, Inc. has a 52 week low of $525.99 and a 52 week high of $1,211.20. The stock has a market capitalization of $63.41 billion, a price-to-earnings ratio of 15.15, a P/E/G ratio of 2.34 and a beta of 0.44. The company's fifty day moving average is $643.90 and its two-hundred day moving average is $733.36. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the firm earned $11.86 earnings per share. The business's revenue was up 10.3% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.61%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.